Monoclonal antibodies emerge as highly active compounds in the treatment of multiple myeloma leading to FDA approval of two molecules just in 2015. In a translational approach, we evaluated the fully human anti-GRP78 antibody PAT-SM6 in vitro and report on a first patient who experienced partial remission after treatment with PAT-SM6 in combination with novel agents. We show, that surface expressed GRP78 suits as target for immunotherapy of MM, especially when considering late stage or relapse-refractory patients. Furthermore, we identified already approved anti-MM drugs to positively modulate GRP78 surface expression, and, as a consequence, to act synergistically with PAT-SM6. These results form the basis for upcoming clinical trials evaluating anti-GRP78 immunotherapy particularly in combination with novel agents in larger cohort of patients with MM. 
Introduction
The development of drug resistance still represents the main obstacle of current multiple myeloma (MM) therapy. Whereas survival has continuously improved for newly diagnosed patients, the prognosis in the relapsed-refractory (RR) setting is still adverse. In a multi-center analysis of 286 patients, the mean overall survival (OS) of bortezomib (btz) and lenalidomide (len) dual-refractory patients was 9 months (1) and even in the era of next generation proteasome and cereblon blocking therapies such as carfilzomib and pomalidomide, OS has only marginally improved varying from 12 to 14 months in recent studies (2) (3) (4) . Even worse is the situation for extramedullary relapsed patients who mostly die from refractory disease within the first year (5, 6) .
Of note, the majority of MM patients will finally become RR illustrating the urgent medical need for new options for patients in this situation.
Glucose regulated protein (GRP) 78 is a heat shock protein (HSP) 70 family member with chaperone activity. It serves as main sensor for misfolded proteins in the endoplasmatic reticulum (ER) and triggers the unfolded protein response.
Furthermore, surface expressed and secreted/soluble variants have been described for various cancer entities. In MM recent articles have highlighted GRP78's role in the mediation of resistance towards proteasome inhibitors (PI) mainly by promoting autophagosome formation -a compensatory mechanism that restores protein degradation in the presence of a blocked proteasome (7, 8) and a similar mechanism was previously described for the BRAF600E inhibitor vemurafenib in melanoma (9) .
On the other hand, removal of GRP78 by drugs or shRNA increased susceptibility to PI in vitro (7, 8) . Furthermore, MM cells surviving PI treatment showed increased GRP78 protein expression, and in MM patients GRP78 expression was associated with progressive disease (8) . These observations are in line with previous findings from solid cancer showing an association between GRP78 expression, stage of disease, invasiveness and drug resistance (10) . It has also been reported that stressed cells from solid cancer frequently translocate GRP78 from the cytosol to the plasma membrane for reasons that remain elusive (11) . We have previously shown that GRP78 is stably and consistently expressed on the cell surface of MM where it can serve as target for immunotherapy (12) . We and others have developed therapeutic antibodies against cell surface GRP78 with promising preclinical and clinical results as single agents (13, 14) . PAT-SM6 is an IgM-type human antibody targeting GRP78 with broad reactivity to cancer including MM (13) . When evaluated with primary MM cells in vitro PAT-SM6 induced apoptosis in a dose dependent manner and complement was fixed and activated as a second mode of action (12) .
Single-agent PAT-SM6 was investigated in a dose-escalating phase I study in RRMM patients. Twelve heavily pretreated patients received four applications of PAT-SM6 with doses ranging from 0.3 to 6mg/kg. Antibody treatment was well tolerated and maximum tolerated dose was not reached. A disease stabilization rate of 33% was observed; however, objective responses according to the international myeloma working group (IMWG) criteria were not observed (15) .
In this paper we show for the first time that treatment of drug resistant MM with the anti-GRP78 antibody PAT-SM6 in combination with novel agents can lead to 
Materials and Methods

Cell lines
Human myeloma cell lines (HMCL) are derived from primary myeloma cells cultured in RPMI 1640 medium supplemented with 5% fetal calf serum (OPM2, MM.1S, MM.1S-DR, LP1-LR) and 3 ng/mL recombinant IL6 for IL-6 dependent cell lines (XG5-BR) as previously described (16) . LP1, OPM-2 and MM.1S were purchased from DSMZ (Braunschweig, Germany) and have been authenticated by DNA profiling as described in detail on the cell bank´s website.
MM.1S-DR, LP1-LR and XG5-BR were obtained after long time exposure of parental cell lines, MM.1S, LP1 and XG5, to dexamethasone (dex), len and btz respectively resulting in the following resistance status: LP1-LR: len resistant; MM1.S-DR: dex resistant; and XG5-BR: len, dex, and btz resistant as previously described (17, 18) .
Resistance to respective drugs was routinely re-confirmed. All HMCL used in this article have been previously extensively characterized, authenticated by phenotype analysis and resistant cell lines were identified with HLA (Human Leukocyte Antigen) typing (16) .
Antibodies
Anti-GRP78 antibody PAT-SM6 (fully human IgM) was produced as outlined elsewhere (12) 
PAT-SM6 immunostaining on bone marrow paraffin sections
Immunohistochemistry (IHC) with PAT-SM6 antibody, GRP78 antibody or control antibodies of intra-and extramedullary MM infiltrates on paraffin sections was performed by trained pathologists with blinded sample groups as previously described (12) . To evaluate the expression of GRP78 / binding of PAT-SM6 antibody on plasma membranes in response to treatment with MM drugs, HMCL MM.1S, OPM2 and LP1-LR were pre-incubated with dex (500nM), len (500nM) or btz (2nM) for 48 hours.
FACS
Cells were washed in PBS and stained with PAT-SM6 and isotype control (ChromPure IgM, Dianova) (5µg/ml) followed by anti-human IgM PE (Dako, 1:100).
Direct and indirect flow cytometric analysis was performed using a FACS LSRII with Diva Software (Beckman Coulter, Miami, FL). Three independent experiments were done for each cell line.
MTT
Cells (1-1.5x10 4 ) were plated into 96-well plates followed by drug treatment for 72h.
Cell viability was measured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay. Three different dose levels were tested: level 1: PAT-SM6 111nM, len 250nM, btz 1nM, Dex 250nM; level 2: PAT-SM6 222nM, len 500nM, dex 500nM, btz 2nM, and level 4: PAT-SM6 444nM, len 1000nM, dex 1000nM, btz 4nM. At the end of each treatment, cells were incubated with 1 mg/mL MTT for 3.5 hours at 37°C; lysis buffer was added and dye absorbance was measured at 570 nm after 18h of incubation. All experiments were repeated 3 times, and each experimental condition was repeated at least in duplicate wells in each experiment.
Compassionate use patient´s characteristics
A 61-year-old male, with newly diagnosed multiple myeloma (IgG kappa, hyperdiploid karyotype) and osteolytic lesions underwent induction therapy with PAD (btz, doxorubicin and dex) followed by stem cell collection and single autologous stem cell transplantation (auto SCT) resulting in a biopsy proven complete remission (CR). Six months later, a serological relapse occurred that was salvaged with 3 cycles of PAD/len. Initially a serological response could be documented, but in the third cycle, still being on len therapy, the patient noticed subcutaneous nodules and swelling of the right testis and extramedullary spread was diagnosed by positron emission tomography/computed tomography PET-CT. A single patient treatment use of PAT-SM6 in combination with len and btz was initiated after informed consent.
Statistical analysis
Data were expressed as mean ±SEM. Statistical analyses were conducted using For the synergism study between PAT-SM6 and myeloma drugs on cell growth inhibition, a combination index (CI) was performed using the data obtained from MTT assay. Drug combination studies were based on concentration effect curves generated as a plot of the fraction of unaffected cells versus drug concentration, in accordance to the Chou and Talalay method (19) using CalcuSyn software (Biosoft, Cambridge, UK). The resulting combination index (CI) values indicate a synergistic effect in drug combinations when < 1, an antagonistic effect when > 1, and an additive effect when equal to 1.
Study approval
The patient was treated on the basis of a single patient treatment use after written 
Activity of anti-MM agents in combination with GRP78 antibody PAT-SM6 in vitro
Combination effects were studied in sensitive myeloma cell lines MM1.S and OPM-2 and resistant cell lines LP1-LR (len resistant), MM1.S-DR (dex resistant) and XG5-BR (len, dex and btz resistant). Single, dual and triple agent combinations were evaluated in varying doses using a simple proliferation assay (MTT) allowing a high throughput analysis. Pretesting experiments were done to determine dose effect curves and the optimal dose ranges for each of the respective drugs as described previously (20) . Within the evaluated doses, single agent dex showed strongest growth inhibition (max. 54%) in sensitive cell lines whereas in vitro-activity of len and PAT-SM6 and btz was moderate (max 36% and 20%, and 25%, respectively). Of note, in triple resistant XG5-BR only PAT-SM6 led to a significant growth inhibition Figure 1A) . In sensitive cell lines double combinations of PAT-SM6 with len or dex were synergistic across all evaluated doses and also synergistic with btz at higher doses in OPM-2 cells (Figure 3 
Discussion
Availability of tumor or lineage specific antigens with robust expression throughout various stages of hematological malignancies is crucial for the design of successful antibody-based therapies. In target expression analysis we observed that in MM cell lines as well as in patients´ specimens, myeloma evolution and drug resistance go along with increased surface GRP78 expression which is in line with previous data from solid cancers, demonstrating an increase in more advanced and refractory stages (21) (22) (23) . This may reflect a functional role of sGRP78 in the mediation of drug resistance but could also occur as an epiphenomenon without biological significance.
In respect of immunotherapy this difference is of less importance since robust target expression is the main requirement. Thus, the preserved target expression at relapse disease while being treated with the four-drug combination btz, len, doxorubicin and dex (PAD Rev regimen) demonstrating resistance against all of the used compounds.
Further de-escalated therapy using len and btz with PAT-SM6 led to a rapid response in both intra-and extramedullary lesions and although duration of response was limited it proves the principal utility of PAT-SM6 as a GRP78 addressing antibody therapy. However, this single patient was treated on compassionate grounds and further controlled studies are warranted to investigate response rates and more effective dose schedules of this drug combination.
If we speculate on the exact mechanism by which PAT-SM6 recaptured response in the patient we need to take the following into consideration: In vitro PAT-SM6
showed a direct cytotoxic effect on MM cells by the induction of apoptosis and the amount of cytotoxicity was positively correlated with the degree of antigen expression. This was previously shown for several MM cell lines (12) and the results of the current study recapitulate this finding by the observation that PAT-SM6 showed single agent activity in XG5-BR cells which exhibit highest sGRP78 expression.
Furthermore, we confirmed PAT-SM6 activity in vivo in the murine 5T33 MM model where PAT-SM6 reduced MM outgrowth in a dose-dependent manner (data not shown). However, in the previous phase I study single-agent PAT-SM6 led to disease stabilization in some patients with RRMM but not to objective responses according to the IMWG criteria (15) . We speculate that both, late stage multi-drug resistant disease, as well as concomitant len treatment led to high sGRP78 expression and consequently to a significant cytotoxicity of PAT-SM6 via induction of apoptosis.
However, in the end the ultimate evidence remains elusive and ongoing studies will protective molecules such as CD55 and CD59 could preserve cells from complement mediated lysis as it was recently observed for daratumumab (25, 26) . Furthermore, newly acquired mutations may alter intracellular signaling and finally prevent the induction of apoptosis by PAT-SM6. Ongoing research currently investigates these hypotheses.
Typical paths of drug development suggest that successful new drugs display singleagent activity, and indeed a recent analysis revealed that also in MM single-agent activity is the best predictor for FDA approval (27) . In regard to the upcoming monoclonal antibodies in MM, to date robust single-agent activity can only be observed in the anti-CD38 addressing antibodies daratumumab and SAR650984 (28,
29).
However, this paradigm is changing, especially since the approval of panobinostata pan-deacetylase inhibitor with only modest activity as single-agent but with high response rates in the combination with btz. In the Panorama 2 trial, around 40% of btz-refractory patients responded to a combination with panobinostat with a PFS of 5.4 months, which clearly indicates that the concept of re-sensitization is feasible (30) . Of note, this re-capture of response was achieved by an increase of side effects including grade 3 diarrhea and fatigue in >20% of the patients. In addition, elotuzumab, a humanized IgG 1 antibody targeting CS-1 showed a disease stabilization rate of only 26.5% in the relapsed setting (31), but when combined with len and dex (Rd) overall response rate (ORR) and progression free survival were significantly superior in a randomized trial (79 vs.66% ORR and 19,4 vs 14,9 months, respectively) (32, 33) . In contrast to panobinostat, this combination therapy was well tolerated and only infusion related reactions, which had been manageable, added to the toxicity profile of Rd. 
The situation is comparable for the anti-GRP78 antibody PAT-SM6. Within the investigated doses no single-agent activity was seen in phase I but in the combination with novel agents efficacy was achieved. It may be argued that a clinical benefit of two months PFS as it was observed in the reported patient is not significant. But it needs to be taken into consideration that we have treated a highly aggressive MM refractory to available standard therapeutics with an investigational agent in an ambiguous dose schedule. Further studies are planned to identify effective doses and synergistic combination partners in clinical trials to increase depth and duration of response in future patients suffering from resistant disease.
We have shown that surface GRP78 can be targeted effectively by a monoclonal antibody, but also intracellular GRP78 increasingly emerges as molecular target for MM therapy. Previous preclinical studies have shown that suppression of intracellular GRP78 (e.g. by the anti-diabetic drug metformin) particularly enhance the cytotoxicity of proteasome inhibitors such as btz (7, 34) . Thus, a cross talk between surface and intracellular GRP78 is likely (35) . In solid cancer sGRP78 is known to regulate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway which itself interacts with the unfolded protein response (36, 37) . We have previously reported that PAT-SM6 is rapidly internalized upon binding to malignant cells which would also allow a direct interaction with intracellular GRP78 (38) . Further studies are warranted to elucidate the biological function of GRP78 and to find additional strategies to overcome drug resistance in MM.
Conclusion
In this paper we demonstrate that sGRP78 can serve as robust target for 
